Pulmonary Hypertension: From Bench to Bedside: 2nd Edition
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: 1 July 2024 | Viewed by 5000
Special Issue Editor
Interests: pulmonary hypertension; right ventricular dysfunction
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pulmonary arterial hypertension is life-threatening diseases caused by constriction and remodeling of pulmonary arteries. Prostacyclin, endothelin receptor antagonist, phosphodiesterase 5 inhibitor and soluble guanylate cyclase stimulator is an available for treatment of pulmonary arterial hypertension, which improve hemodynamics and exercise capacity. However, sufficient improvement of long-term prognosis is not achieved in all patients with pulmonary arterial hypertension. New findings from basic research contribute to therapeutic advances of pulmonary arterial hypertension. In this special issue, we focus on basic research in pulmonary arterial hypertension.
Volume I: https://www.mdpi.com/journal/life/special_issues/pulmonary_hypertension_2022
Dr. Satoshi Akagi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary arterial hypertension
- chronic thromboembolic pulmonary hypertension
- imaging
- physiological tests
- genetics
- inflamation
- metabolic dysfunction
- proriferative signaling